|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006754,
umls-concept:C0006826,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0036525,
umls-concept:C0069717,
umls-concept:C0282460,
umls-concept:C1513822,
umls-concept:C1519810,
umls-concept:C1522484,
umls-concept:C1880171,
umls-concept:C2239176
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-10-10
|
|
pubmed:abstractText |
Prolonged survival for patients with unresectable hepatocellular carcinoma (HCC) is consistently reported at lower than 6 months. Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
pubmed-author:BelaniChandra PCP,
pubmed-author:ChuPeiguo GPG,
pubmed-author:ChungVincentV,
pubmed-author:GandaraDavid RDR,
pubmed-author:LenzHeinz-JosefHJ,
pubmed-author:LeongLucille ALA,
pubmed-author:LimDean WDW,
pubmed-author:LongmateJeffrey AJA,
pubmed-author:MarxHowardH,
pubmed-author:MorganRobert JRJ,
pubmed-author:RamanathanRamesh KRK,
pubmed-author:ShibataStephen ISI,
pubmed-author:WagmanLawrence DLD,
pubmed-author:WagmanStephen DSD,
pubmed-author:YenYY
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
317-22
|
|
pubmed:dateRevised |
2009-2-20
|
|
pubmed:meshHeading |
pubmed-meshheading:18845988-Adult,
pubmed-meshheading:18845988-Aged,
pubmed-meshheading:18845988-Aged, 80 and over,
pubmed-meshheading:18845988-Antineoplastic Agents,
pubmed-meshheading:18845988-Carcinoma, Hepatocellular,
pubmed-meshheading:18845988-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18845988-Cholangiocarcinoma,
pubmed-meshheading:18845988-Female,
pubmed-meshheading:18845988-Humans,
pubmed-meshheading:18845988-Liver Neoplasms,
pubmed-meshheading:18845988-Male,
pubmed-meshheading:18845988-Middle Aged,
pubmed-meshheading:18845988-Neoplasm Recurrence, Local,
pubmed-meshheading:18845988-Organoplatinum Compounds,
pubmed-meshheading:18845988-Prognosis,
pubmed-meshheading:18845988-Salvage Therapy,
pubmed-meshheading:18845988-Survival Rate,
pubmed-meshheading:18845988-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
|
|
pubmed:affiliation |
Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010-3000, USA. yyen@coh.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
